Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis.
Loretta
L
Fala
N Engl J Med. 2014 Jul 24;371(4):326-38
25007392
Br J Dermatol. 2015 Feb;172(2):484-93
25132411
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90
25243910
J Am Acad Dermatol. 2015 Jun;72(6):961-7.e5
25882886